Table 2.
Prevalence and participants with potential DDIs in the Lifelines cohort.
| Variables | Prevalence of potential DDIs (n = 1,199) |
Variables | Participants with potential DDIs (n = 1,125) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age in years [mean (SD)] |
P-value | Gender [mean (SD)] |
P-value | Age in years [n (%)] |
P-value | Gender [n (%)] |
P-value | ||||||
| 18-59 | >=60 | Men | Women | 18-59 | >=60 | Men | Women | ||||||
| CYP2D6 (n = 488) | 0.006 (0.09) | 0.006 (0.01) | 0.519 | 0.005 (0.08) | 0.006 (0.08) | 0.048 | CYP2D6 (n = 448) | 349 (0.54) | 99 (0.62) | 0.227 | 118 (0.46) | 330 (0.59) | 0.018 |
| CYP2C19 (n = 513) | 0.006 (0.08) | 0.009 (0.09) | 0.0002 | 0.006 (0.08) | 0.007 (0.08) | 0.428 | CYP2C19 (n = 490) | 351 (0.54) | 139 (0.87) | 0.000002 | 148 (0.58) | 342 (0.62) | 0.527 |
| CYP2C9 (n = 198) | 0.003 (0.05) | 0.002 (0.05) | 0.178 | 0.002 (0.04) | 0.003 (0.05) | 0.037 | CYP2C9 (n = 187) | 156 (0.24) | 31 (0.19) | 0.264 | 47 (0.18) | 140 (0.25) | 0.060 |
SD, Standard Deviation; DDI, drug-drug interaction.